Vicore Pharma Holding (NASDAQ:VCRE) Stock Short Interest Report for September

Vicore Pharma Holding (NASDAQ:VCRE) was the recipient of a significant drop in short interest in September. As of September 30th, there was short interest totaling 4,238 shares, a drop of 57.0% from the September 15th total of 9,857 shares. Based on an average trading volume of 39,075 shares, the days-to-cover ratio is presently 0.1 days.

Vicore Pharma Stock Performance

NASDAQ VCRE traded down $0.25 during trading on Tuesday, reaching $8.98. The company’s stock had a trading volume of 23,257 shares, compared to its average volume of 27,891. Vicore Pharma has a twelve month low of $7.88 and a twelve month high of $17.80.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on VCRE shares. Weiss Ratings started coverage on Vicore Pharma in a research note on Thursday. They set a “sell (e-)” rating for the company. Jefferies Financial Group assumed coverage on shares of Vicore Pharma in a research note on Friday. They issued a “buy” rating and a $25.00 price target on the stock. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $25.00.

About Vicore Pharma

Vicore Pharma is a Swedish biopharmaceutical company focused on developing medicines for severe respiratory and pulmonary diseases. The company’s research is centered on treatments intended to address the underlying disease processes associated with conditions such as idiopathic pulmonary fibrosis and other forms of progressive lung fibrosis.

Vicore’s lead investigational program is buloxibutid, formerly known as C21, an orally administered small-molecule agonist of the angiotensin II type 2 receptor.